Abstract
The article deals with the role of pharmacological agents and implantable devices in the treatment of chronic heart failure (CHF) with different ejection fraction: preserved ejection fraction, mildly reduced ejection fraction and reduced ejection fraction (HFpEF, CHFmrEFV, CHFrFV). The authors emphasise that despite the widespread introduction of angiotensin receptor and neprilysin inhibitor (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MCRAs) and sodium-glucose cotransporter inhibitors (SGLT2) into practice, there is still a high residual risk of unfavorable outcomes in patients with both HFpEF and CHFmrEFV, CHFrFV. Therefore, therapies using implantable cardioverter-defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) are evolving. The review is based on data from PubMed and Google Scholar databases for the last 5 years.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call